youtube
CVS Health delivered a strong second-quarter earnings beat, raising its full-year adjusted EPS guidance while projecting annual revenue to reach at least 414 billion dollars. While strong execution across business segments continues to drive top-line momentum, regulatory risks and drug pricing headwinds have kept quantitative ratings at a Hold. With management establishing a long-term earnings floor of 8.44 dollars per share for 2027, investors must weigh immediate industry pressures against the pharmacy giant's long-term financial targets.
|
